Vertex Starts Pivotal CF Trials

Luke Timmerman5/27/09

Vertex Pharmaceuticals (NASDAQ: VRTX), the Cambridge, MA-based biotech company which has significant operations in San Diego, said today it has started a pivotal clinical trial program for its drug candidate for cystic fibrosis, a genetic lung disease. The company is running a series of three trials of VX-770, a drug that aims to be the first of its kind to target the defective protein that causes cystic fibrosis. The trials will aim to enroll 240 patients at 110 clinical trial sites in North America, Europe, and Australia.

Luke Timmerman is the National Biotech Editor of Xconomy. E-mail him at ltimmerman@xconomy.com Follow @